(Español) 59° Congreso Argentino de Neurología
15/11/2022
Bioprofarma Bagó Announces In-Licensing Exclusive Partnership with Polaris Pharmaceuticals to introduce ADI-PEG20 (ADZODI®), an innovative First in class arginine degradation platform for hard-to-treat cancers in Argentina and other LATAM markets.
Buenos Aires, Argentina – Bioprofarma Bagó (a fully owned subsidiary of GRUPO EMPRESARIAL BAGO), today announced an exclusive licensing agreement with Polaris, a renowned American pharmaceutical company, to introduce ADI-PEG20 (ADZODI®), a novel treatment for Malignant Pleural Mesothelioma (MPM) to the LATAM. This partnership is set to improve the treatment landscape by delivering innovative therapeutic […]
New release LIPECELTE® trabectedin
Introducing LIPECELTE® Trabectedin: A New Addition to Our Oncology Line At Bioprofarma Bagó, we reaffirm our dedication to patient care with the launch of LIPECELTE® trabectedin, approved by ANMAT for the treatment of: – Advanced soft tissue sarcoma (STS) in adult patients who have failed anthracycline and ifosfamide treatment or are not candidates for these […]
(Español) Jornada de Uro Oncología FUCDIM
Sorry, this entry is only available in European Spanish.